Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2025)

Historic Long-Term Investments for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $67.2 million.

  • 4D Molecular Therapeutics' Long-Term Investments rose 3769.24% to $67.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.2 million, marking a year-over-year increase of 3769.24%. This contributed to the annual value of $80.6 million for FY2024, which is 63564.91% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Long-Term Investments of $67.2 million as of Q3 2025, which was up 3769.24% from $123.8 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Long-Term Investments peaked at $137.0 million during Q1 2025, and registered a low of $1.4 million during Q1 2023.
  • For the 5-year period, 4D Molecular Therapeutics' Long-Term Investments averaged around $52.4 million, with its median value being $48.8 million (2024).
  • In the last 5 years, 4D Molecular Therapeutics' Long-Term Investments crashed by 9709.48% in 2023 and then surged by 437985.77% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' Long-Term Investments (Quarter) stood at $67.7 million in 2021, then tumbled by 92.75% to $4.9 million in 2022, then soared by 123.19% to $11.0 million in 2023, then soared by 635.65% to $80.6 million in 2024, then decreased by 16.65% to $67.2 million in 2025.
  • Its last three reported values are $67.2 million in Q3 2025, $123.8 million for Q2 2025, and $137.0 million during Q1 2025.